GENESIS pharma

The leading Greek pharmaceutical company GENESIS Pharma was founded with the mission to address unmet patient needs through innovation. It was one of the first pharmaceutical companies in Europe to specialize in the marketing, sales and distribution of biopharmaceutical products and is currently the largest by turnover among Greek companies focusing on innovative medicines.

Through long-standing strategic partnerships with some of the leading global pharmaceutical companies committed to cutting-edge R&D, GENESIS Pharma has created a strong portfolio of innovative and high therapeutic value pharmaceutical products for more than 30 severe and rare diseases.

With extensive expertise in the field of hematology-oncology, the company has a wide range of innovative medicines for rare hematological malignancies, including multiple myeloma, myelodysplastic syndromes, types of leukemia and lymphomas, as well as oncology medicines for breast and ovarian cancer and osteosarcoma.

GENESIS pharma
Founded: 1997


It is acknowledged as one of the most specialized companies in multiple sclerosis in Greece with an extensive product portfolio for the disease and an expertise of more than 20 years, as it exclusively represents Biogen, a leading company in multiple sclerosis and neuroscience research worldwide. In addition, its significant activity in biotechnology has expanded in recent years in the field of biosimilar medicines, with a biosimilars portfolio of advanced biologics for a range of rheumatological, dermatological and gastrointestinal chronic inflammatory diseases.

Its portfolio also includes pioneering treatments for rare genetic diseases. Amongst these, the first therapy approved for the treatment of spinal muscular atrophy (SMA), the first oral treatment coming from research in precision medicine for Fabry disease, as well as 3 first-in-class siRNA therapeutics, based on Nobel Prize-winning science, for hATTR amyloidosis, primary hyperoxaluria and acute hepatic porphyria.

The company’s extended product portfolio is complemented by branded pharmaceuticals in the fields of dermatology, rheumatology, nephrology and cardiology as well as an intravenous iron replacement product.

GENESIS Pharma is one of the most awarded companies in the country for its commitment to sustainable development and good working environment, with a yearly contribution to the Greek economy and society that exceeds 30% of its annual turnover.

Number of employees: (12/2021) :

Turnover (2021):
€125.85 million

Awards: CR Index 2020-2021 (Platinum Award), Best Workplaces (2018-2019, 19 national and European distinctions since 2003), The Most Sustainable Companies in Greece 2021/QualityΝet Foundation

International partners:
Alnylam Pharmaceuticals, Amicus Therapeutics, Biogen, Celgene, Incyte, PharmaMar, SEAGEN, Takeda, Vifor Fresenius Medical Care Renal Pharma, Vifor Pharma, JAZZ Pharmaceuticals


Skip to content